Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.

The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.

The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc.

Country	United States
Founded	2016
Industry	Biotechnology
Sector	Healthcare
CEO	Gareth Sheridan

Contact Details

Address: 121 South Orange Avenue, Suite 1500 Orlando, Florida 32801 United States
Phone	407 377 6695
Website	nutriband.com

Stock Details

Ticker Symbol	NTRBW
Exchange	NASDAQ
Stock Type	Warrants
Fiscal Year	February - January
Reporting Currency	USD
CIK Code	0001676047
CUSIP Number	67092M125
ISIN Number	US67092M1255

Key Executives

Name	Position
Gareth Sheridan	Founder, Chief Executive Officer and Director
Serguei Melnik	Founder, President, Company Secretary and Executive Chairman of the Board
Gerald Goodman	Chief Financial Officer and Chief Accounting Officer
Dr. Alan Smith Ph.D.	Chief Operating Officer and President of 4P Therapeutics
Dr. Jeffrey Patrick Pharm.D.	Chief Scientific Officer
Michael Myer	President of Pocono Pharmaceutical
Tyler Overk	Head of Active Intelligence